TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21190995
Drug: Partly self-administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Partly self-administered exercise intervention
Study: 17005076
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Chinese medicine (Synthetic group)
Study: 1898697
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy (0.2 mg/kg per day)
Study: 1898697
Drug: Hyperinsulinemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic clamp (insulin concentration > 1435 pmol/L)
Study: 6849746
Drug: i.v. nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. nicardipine (0.5-20 mg)
Study: 6849746
Drug: Oral nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nicardipine (10-40 mg)
Study: 2792112
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg nicardipine
Study: 30859995
Drug: AR19 (20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR19 (20-mg capsule)
Study: 30859995
Drug: Reference (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference (2 x 10-mg tablets)
Study: 17909087
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg once daily for 6 weeks
Study: 8720432
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) infusion at 1, 10, and 100 ng/min/dl forearm volume
Study: 8720432
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (ANF) infusion
Study: 1505903
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (PN)
Study: 1633010
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (PN) plus biosynthetic human growth hormone (bGH) 4 UI/daily
Study: 3534588
Drug: One cycle
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of CMF chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil) preoperatively
Study: 3534588
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (not specified in detail)
Study: 22033034
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) chemotherapy with cisplatin/paclitaxel
Study: 22033034
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) chemotherapy with carboplatin followed by cisplatin/paclitaxel
Study: 22033034
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with low pre-chemotherapy CA125 levels
Study: 19039946
Drug: Impaza (superlow-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impaza (superlow-dose antibodies to endothelial NO synthase)
Study: 12775314
Drug: Clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clobetasone butyrate 0.05% cream
Study: 8911885
Drug: Sodium tiludronate
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium tiludronate 200 mg
Study: 8911885
Drug: Sodium tiludronate
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium tiludronate 400 mg
Study: 8911885
Drug: Sodium tiludronate
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium tiludronate 600 mg
Study: 8911885
Drug: Sodium tiludronate
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium tiludronate 800 mg
Study: 7125264
Drug: Midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3 mg/kg)
Study: 3731680
Drug: Diazepam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.3 mg/kg)
Study: 4059300
Drug: Thiopentone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (5 mg/kg)
Study: 9702844
Drug: Diphenhydramine 25
Normalized name: DIPHENHYDRAMINE 25MG CHEW TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 25 mg
Study: 21159473
Drug: Midazolam 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 1.5 mg
Study: 20565296
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin B injections)
Study: 11766999
Drug: Amitriptyline (75-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75-150 mg/day)
Study: 7934151
Drug: Terbutaline via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline via Turbuhaler (1.0 mg)
Study: 7934151
Drug: Terbutaline via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline via Turbuhaler (2.5 mg)
Study: 7934151
Drug: Terbutaline via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline via CFC inhaler (1.0 mg without Nebuhaler)
Study: 7934151
Drug: Terbutaline via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline via CFC inhaler (2.5 mg with Nebuhaler)
Study: 3073868
Drug: Interferon (Wellferon)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (Wellferon) at doses of 5 MU/m2 i.m. daily for the first 4 weeks and three times weekly for 5 months thereafter
Study: 30553700
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of RG7800
Study: 21114770
Drug: Bupropion-SR 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion-SR 150 mg/day for 2 months
Study: 7700071
Drug: Cilazapril (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.5-5 mg, once daily for 12 weeks)
Study: 7700071
Drug: Nitrendipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10-20 mg, once daily for 12 weeks)
Study: 2607127
Drug: Lofepramine (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofepramine (140 mg)
Study: 31853543
Drug: Machine Learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine Learning (ML)
Study: 30075596
Drug: Electrophysiological study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrophysiological study (ES) positive, treated by catheter ablation and/or device implants
Study: 30075596
Drug: Electrophysiological study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrophysiological study (ES) negative, no interventional treatment
Study: 27206810
Drug: Hydralazine/isosorbide dinitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine/isosorbide dinitrate (HYIS) 50 mg/20 mg t.i.d. for 24 weeks
Study: 25782469
Drug: 2.25 g
Normalized name: Zosyn 2.25 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g SMO.IR and placebo alcohol preparation
Study: 25782469
Drug: 2.25 g
Normalized name: Zosyn 2.25 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g SMO.IR and alcohol
Study: 25782469
Drug: 2.25 g
Normalized name: Zosyn 2.25 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g SMO.IR matching placebo and alcohol
Study: 25782469
Drug: 2.25 g
Normalized name: Zosyn 2.25 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.25 g SMO.IR matching placebo and placebo alcohol preparation
Study: 23453866
Drug: AGE-S (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGE-S (250 mg aged garlic extract, 100 μg vitamin B12, 300 μg folic acid, 12.5 mg vitamin B6, 100 mg L-arginine)
Study: 19640315
Drug: Intratympanic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic methylprednisolone injections
Study: 2533450
Drug: Danazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (200 mg three times a day)
Study: 2526031
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (100 mg a day)
Study: 2526031
Drug: Danazol and
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol and high-dose MPA
Study: 925164
Drug: Rational (cognitive)
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational (cognitive) restructuring treatment
Study: 31586772
Drug: Melatonin 25
Normalized name: calcium phosphate/melatonin 250 mg-1.5 mg ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 25 mg
Study: 31101403
Drug: Bexagliflozin, 20mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin, 20mg, daily for 24 weeks
Study: 22422736
Drug: 3-drug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-drug chemotherapy (including doxorubicin) with or without lung radiation
Study: 22422736
Drug: 2-drug chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-drug chemotherapy (dactinomycin and vincristine)
Study: 18603457
Drug: Cannabinoid (delta‐9‐tetrahydrocannabinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabinoid (delta‐9‐tetrahydrocannabinol (THC) and cannabidiol mixture) as an oromucosal spray
Study: 16299295
Drug: MSP3-LSP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP3-LSP vaccine with Montanide ISA 720
Study: 16299295
Drug: MSP3-LSP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP3-LSP vaccine with aluminum hydroxide
Study: 16299295
Drug: MSP3-LSP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP3-LSP vaccine
Study: 12435326
Drug: Pharmacological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapies for OA
Study: 12435326
Drug: Cochrane systematic
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochrane systematic reviews of OA therapies
Study: 9790423
Drug: Benznidazole at
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole at a dose of 5 mg/kg/day for 60 days
Study: 7199836
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of morphine epidurally
Study: 7199836
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of morphine intramuscularly
Study: 28651804
Drug: Trabectedin 1.5mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.5mg/m2 by 24‐hour IV infusion
Study: 28651804
Drug: Dacarbazine 1g/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine 1g/m2 by 20‐120‐minute IV infusion once every three weeks
Study: 25015203
Drug: Long-course preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course preoperative CRT (50.4 Gy in 28 fractions, per oral tegafur-uracil and L-leucovorin)
Study: 11447952
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg ketamine + 0.1 mg/kg diazepam
Study: 9727815
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly buprenorphine maintenance in primary care clinic
Study: 9727815
Drug: Traditional drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional drug treatment program
Study: 2683836
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP) 4 puffs of 50 micrograms b.i.d.
Study: 1114148
Drug: Salbutamol (predominantly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (predominantly β‐2 stimulant)
Study: 1114148
Drug: Practolol (predominantly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (predominantly β‐1 blocking agent) with Salbutamol
Study: 24535377
Drug: β-blocker therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blocker therapy
Study: 24080100
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment (scaling and root planing for a minimum of two 90-minute sessions, plus antibacterial mouth rinse for at least 32 days)
Study: 24080100
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received periodontal treatment after 6 months)
Study: 20847112
Drug: Tea tree
Normalized name: tea tree
DrugBank: Melaleuca alternifolia leaf (DB14372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea tree oil treatment
Study: 7828454
Drug: Methionyl growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionyl growth hormone (0.3 mg/kg/week) administered daily
Study: 7828454
Drug: Methionyl growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionyl growth hormone (0.3 mg/kg/week) administered 3 times per week (TIW)
Study: 3513581
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone (4 capsules of 100 mg each)
Study: 3513581
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules)
Study: 3513581
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone
Study: 22954616
Drug: Org 26576
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 26576 (450 mg BID)
Study: 22954616
Drug: Org 26576
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 26576 (400 mg BID)
Study: 20195651
Drug: Bracing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bracing treatment for idiopathic scoliosis
Study: 20195651
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (existing treatment)
Study: 10461109
Drug: Tamm‐Horsfall protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamm‐Horsfall protein excretion in pure uric acid stone formers
Study: 10461109
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid excretion in pure uric acid stone formers (group I)
Study: 10461109
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid excretion in mixed stone formers (group II)
Study: 10461109
Drug: Calcium excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium excretion in mixed stone formers (group II)
Study: 10461109
Drug: Citrate excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate excretion in both groups (I and II)
Study: 8903836
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 3 IU m‐2 daily
Study: 8903836
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 6 IU m‐2 daily
Study: 26151676
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1,000 mg plus prednisone/prednisolone 5 mg twice daily
Study: 26151676
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus prednisone/prednisolone 5 mg twice daily
Study: 19917838
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF)
Study: 19917838
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin and fluorouracil (PF)
Study: 12752352
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g sachet (micropellets) mesalazine formulation
Study: 12752352
Drug: Three enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three enteric‐coated tablets (500 mg each, Claversal)
Study: 9311056
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (2 x 1,000 micrograms/day)
Study: 3487259
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg bw methylprednisolone
Study: 3487259
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg bw dexamethasone
Study: 3487259
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg hydrocortisone
Study: 16570889
Drug: Auto-transfusion system
Normalized name: Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-transfusion system with re-infusion of drained blood
Study: 16570889
Drug: Methylprednisolone administration
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone administration before blood re-perfusion
Study: 10930149
Drug: AZT 100
Normalized name: AZT 100 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT 100 mg three times daily plus ddC 0.375 mg three times daily (half dose)
Study: 10930149
Drug: AZT 200
Normalized name: AZT 200 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZT 200 mg three times daily plus ddC 0.75 mg three times daily (standard dose)
Study: 8436638
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg bid) under supervision
Study: 27550537
Drug: Lycopene-enriched virgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene-enriched virgin olive oil spray (n = 30)
Study: 27550537
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray (n = 30)
Study: 23789370
Drug: Rectal suppositories
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppositories vitaprost plus once a day for 10 days before and after surgery
Study: 23789370
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg 2 times a day for 10 days before and after surgery (Control group)
Study: 23789370
Drug: Rectal suppositories
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppositories vitaprost plus
Study: 23789370
Drug: Pefloxacin 400
Normalized name: pefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 400 mg 2 times a day (Control group)
Study: 21972621
Drug: Medication (Enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Enteric-coated aspirin)
Study: 15533466
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTX‐A) injection (100 to 200 U of Dysport or Botox)
Study: 30829777
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTX‐A) injection
Study: 8116561
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of fructose
Study: 1753719
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg caffeine
Study: 31398441
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg caffeine
Study: 20399993
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of Mycophenolate mofetil (MMF) 500 mg
Study: 20399993
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of Mycophenolate mofetil (MMF) 500 mg
Study: 18397979
Drug: Outpatient 1-year
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient 1-year intervention program based on exercise, behavior, and nutrition therapy
Study: 2009843
Drug: Triazolam, 0.125
Normalized name: Triazolam, 0.125 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam, 0.125 mg
Study: 16635226
Drug: Motilin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motilin infusion
Study: 6128230
Drug: Somatostatin and
Normalized name: Somatostatin and analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin and motilin together infusion
Study: 21320549
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of PCV7
Study: 21320549
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of PCV7
Study: 22326775
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or two doses of PCV7
Study: 17601990
Drug: Euglycemic-hyperinsulinemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemic-hyperinsulinemic clamp (1.2 mU x kg(‐1) x min(‐1) insulin)
Study: 16518992
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) levels of 93-99 mg/dl
Study: 16518992
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) levels of 100-125 mg/dl
Study: 10529122
Drug: 5 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg/kg of recombinant human IL-10 (rhIL-10) daily for 28 days
Study: 10529122
Drug: 10 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg/kg of recombinant human IL-10 (rhIL-10) daily for 28 days
Study: 8622104
Drug: Isepamicin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin (15 mg/kg or 8 mg/kg once daily)
Study: 8622116
Drug: Amikacin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (7.5 mg/kg twice daily)
Study: 31911147
Drug: Islatravir (0.5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir (0.5-30 mg single oral dose)
Study: 31911147
Drug: Islatravir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir (10 mg dose)
Study: 31911147
Drug: Islatravir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir (0.5 mg dose)